查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1950421

腺結合病毒載體生產CDMO市場按服務類型、生產能力、生產平台、血清型、治療用途和最終用戶分類，全球預測，2026-2032年

Adeno-Associated Virus Vector Production CDMO Market by Service Type, Production Scale, Production Platform, Serotype, Therapeutic Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腺結合病毒載體生產 CDMO 市值將達到 21.5 億美元，到 2026 年將成長至 25 億美元，到 2032 年將達到 52.5 億美元，複合年成長率為 13.60%。

關鍵市場統計數據
基準年 2025 21.5億美元
預計年份：2026年 25億美元
預測年份 2032 52.5億美元
複合年成長率 (%) 13.60%

一個簡潔的產業框架，闡述了技術選擇和生產執行如何整合以實現AAV載體計畫的臨床和商業化應用。

腺結合病毒載體的生產處於生物創新和複雜製造流程的交匯點，需要合約研發生產機構（CDMO）具備深厚的技術專長和戰略遠見。目前，該行業面臨多重壓力：不斷發展的治療方法、監管機構對可比性和產品特性日益嚴格的審查，以及持續將實驗室製程規模化應用於臨床並最大限度降低風險的需求。隨著研發人員推進臨床試驗，重點正從概念驗證轉向可重複性、分析穩健性和供應可靠性，這使得專業服務供應商的角色日益重要。

權威觀點了技術標準化、平台整合和下游創新如何重新定義供應商價值和專案風險分配。

腺結合病毒載體生產領域正經歷變革性的轉變，重塑供應商的專業技術、資本投資和平台策略。首先，以效力和純度檢測為核心的技術標準化浪潮，提高了人們對不同專案間可比性的期望，使得能夠展示檢驗的分析套件和可重複方法的供應商更具優勢。因此，那些將可靠的效力檢測和正交純度測試整合到其服務中的製造商，正日益被視為戰略合作夥伴，而非單純的交易型供應商。

對關稅主導的供應鏈動態和籌資策略的詳細影響分析，這些動態和策略正在改變先進載體生產的成本結構、供應商關係和專案韌性。

美國2025年實施的累積關稅為先進生物製藥及其配套供應鏈的原料採購帶來了顯著的複雜性，腺結合病毒生產生態系統也不例外。關稅導致的投入成本上漲給原料採購選擇帶來了壓力，推動了關鍵試劑的垂直整合，並促使供應商重新評估其全球籌資策略。這些反應體現在上游投入品的各個方面，例如質體、轉染試劑、一次性組件和層析法樹脂，不斷變化的成本動態正在影響企業的內部內部資源和外包決策。

將服務能力、生產平台、治療重點和血清型選擇與供應商的適用性和項目成果聯繫起來的綜合細分資訊

了解市場機會和供應商契合度需要深入了解服務線、生產規模、表達系統、平台、治療標靶、最終用戶和血清型如何交織，從而塑造技術需求和夥伴關係預期。服務類型方面的考慮因素包括效力和純度檢測等分析服務，這些檢測是可比性和放行決策的基礎；以及上游工程的選擇，例如穩定表達和瞬時轉染，這決定了批次一致性和時間安排的柔軟性。下游製程包括層析法和超過濾流程，其中層析法可進一步分為親和性層析法和離子交換層析法。超過濾通常採用切向流過濾。填充和包裝能力涵蓋從預填充式注射器到管瓶填充，對臨床和商業包裝策略至關重要。

區域策略考量：解釋監管環境、人才庫和物流如何影響全球市場中的製造地和供應商選擇。

區域趨勢將顯著影響美洲、歐洲、中東和非洲以及亞太地區的申辦者和服務供應商如何優先考慮產能、監管溝通和物流規劃。在美洲，臨床開發活動和先進製造技術的集中有利於快速擴大生產規模和密切的監管合作，這有利於那些尋求製程開發與臨床專案緊密結合的申辦方。該地區的供應商生態系統往往強調提供一體化服務、接近性關鍵研發機構以及快速採購週期，所有這些都非常適合時間緊迫的專案。

能力映射凸顯了檢驗的分析技術、多元化的營運以及夥伴關係主導的服務模式的重要性，這些因素決定了供應商在載體製造領域的競爭地位。

在先進載體生產領域，競爭差異化取決於公司層面的動態。領先的服務供應商兼具技術深度、監管經驗和營運擴充性。頂級企業通常會大力投資於檢驗的分析平台、統一的效力和純度測試以及標準化的純化生產線，以降低變異性並加快可比性。這些投資有助於從臨床階段到商業化階段的無縫過渡，並支持更可預測的監管互動。

為專案發起人提供切實可行的建議，以確保其合約和籌資策略的分析穩健性、平台柔軟性和供應鏈韌性。

產業領導者應採取切實可行的措施，將策略洞察轉化為營運和合約優勢。首先，將嚴格的分析基準測試納入供應商選擇標準。具體而言，供應商應要求提供檢驗的效價和正交純度測試、完善的方法轉移通訊協定以及可最大限度降低放大生產過程中可比性風險的重現性指標。儘早明確分析要求可以減少下游環節的延誤，並明確遵守路徑。

採用透明的多學科方法，結合專家諮詢、技術文獻綜合和情境分析，為製造決策者提供可操作的見解。

本分析的調查方法結合了多維度的證據流和結構化的專家意見收集，以確保獲得可靠且可操作的見解。關鍵投入包括與生產專家、分析科學家、法規顧問和採購人員進行訪談和結構化諮詢，以收集關於製程選擇、技術轉移複雜性和供應商能力的全面定性見解。這些關鍵見解與載體生物學的二手技術文獻、層析法和過濾技術領域同行評審調查方法的最新進展以及關於可比性和品質要求的官方監管指南進行了三角驗證。

權威的綜合分析表明，技術可行性、監管合規性和穩健的採購對於確保基因治療計畫可靠的生產成果至關重要。

腺結合病毒載體生產生態系統正處於轉折點，卓越的執行力、充分的監管準備和強大的供應鏈韌性將決定專案能否成功，避免遭遇重大衝擊。技術選擇，包括表達系統選擇、平台策略和下游純化架構，對製程穩健性、可比較性要求以及患者用藥時間都具有顯著影響。優先考慮檢驗的分析方法、靈活的平台藍圖和多來源策略的申辦方，將能夠降低專案風險並保留策略選擇權。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章腺結合病毒載體生產CDMO市場（依服務類型分類）

  • 分析服務
    • 功效測試
    • 純度測試
  • 下游工藝
    • 層析法
      • 親和性和層析法
      • 離子交換層析法
    • 超過濾
  • 填充和精加工
    • 預填充式注射器
    • 管瓶填充
  • 上游工程
    • 穩定表達
    • 瞬時轉染

第9章腺結合病毒載體生產CDMO市場（依生產規模分類）

  • 臨床階段
    • 第一階段
    • 第三階段
    • 第二階段
  • 商業的
  • 臨床前

第10章腺結合病毒載體生產CDMO市場（依生產平台分類）

  • 穩定生產細胞株
  • 瞬時轉染
    • 脂質體轉染
    • 聚乙烯亞胺介導的轉染

第11章腺結合病毒載體生產CDMO市場（依血清型分類）

  • AAV2
  • AAV8
  • AAV9

第12章腺結合病毒載體生產CDMO市場（依治療應用分類）

  • 遺傳性疾病
    • 血友病
    • 肌肉萎縮症
  • 神經系統疾病
    • 阿茲海默症
    • 帕金森氏症
  • 腫瘤學

第13章腺結合病毒載體生產CDMO市場（依最終用戶分類）

  • 學術研究機構
  • 生技公司
  • 製藥公司

第14章腺結合病毒載體生產CDMO市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章腺結合病毒載體生產CDMO市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國腺結合病毒載體生產CDMO市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國：腺結合病毒載體生產CDMO市場

18. 中國：腺結合病毒載體生產CDMO市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AGC Biologics Co., Ltd.
  • Aldevron, LLC
  • BioCentriq, Inc.
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Biogene, Inc.
  • FUJIFILM Diosynth Biotechnologies USA, Inc.
  • Genezen Laboratories, Inc.
  • GenScript Biotech Corporation
  • Kaneka Eurogentec SA
  • Lonza Group AG
  • Merck KGaA
  • Novasep SA
  • Oxford Biomedica PLC
  • ProBio, Inc.
  • Resilience, Inc.
  • Samsung Biologics Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • VGXI LLC
  • Wuxi AppTec Co., Ltd.
Product Code: MRR-4F7A6D4FD853

The Adeno-Associated Virus Vector Production CDMO Market was valued at USD 2.15 billion in 2025 and is projected to grow to USD 2.50 billion in 2026, with a CAGR of 13.60%, reaching USD 5.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.15 billion
Estimated Year [2026] USD 2.50 billion
Forecast Year [2032] USD 5.25 billion
CAGR (%) 13.60%

A concise industry framing that explains how technical choices and manufacturing execution converge to determine clinical translation and commercial readiness for AAV vector programs

Adeno-associated virus vector production stands at the intersection of biological innovation and complex manufacturing execution, requiring deep technical competence and strategic foresight from contract development and manufacturing organizations. The industry now faces simultaneous pressures from evolving therapeutic modalities, tighter regulatory scrutiny on comparability and product characterization, and a persistent need to scale processes from bench to bedside with minimal risk. As developers progress through clinical inflection points, the emphasis shifts from proof of concept to reproducibility, analytical robustness, and supply reliability, which in turn elevates the role of specialized service providers.

Practically speaking, program sponsors and manufacturing partners must integrate upstream decisions about expression systems and production platforms with downstream realities of purification, analytics, and fill-finish pathways. This integration influences not only process yields and product quality but also regulatory dossiers and commercial readiness. Furthermore, technology choices such as transient transfection versus stable producer cell lines reverberate across timelines, cost profiles, and operational risk. In this context, an informed procurement posture is essential; sponsors that combine technical due diligence with supplier capability assessments can reduce program uncertainty and accelerate clinical milestones.

Looking ahead, the industry's maturation will be defined less by novelty and more by execution excellence: reproducible analytics, scalable purification, validated fill-finish workflows, and resilient supply chains. The following sections unpack transformative shifts, tariff-driven headwinds, segmentation-driven opportunity areas, regional strategic implications, and concrete recommendations for leaders seeking to translate insight into competitive advantage.

An authoritative overview of how technological standardization, platform consolidation, and downstream innovations are redefining supplier value and program risk allocation

The landscape for adeno-associated virus vector production is undergoing transformative shifts that reshape vendor specialization, capital deployment, and platform strategy. First, a wave of technological standardization around potency and purity assays is leading to greater comparability expectations across programs, creating a premium for providers who can demonstrate validated analytical suites and reproducible methods. As a result, manufacturers that integrate robust potency assays and orthogonal purity testing into their service offering are increasingly viewed as strategic partners rather than transactional suppliers.

Second, process platform decisions are consolidating strategic priorities. The tension between transient transfection and stable producer cell lines is no longer solely a scientific debate; it is a commercial calculus that determines workforce skills, facility design, and long-term cost structure. Providers investing in scalable platforms, whether based on stable expression systems or refined transient methods, will be better positioned to capture follow-on demand as programs mature. Third, downstream innovations such as affinity chromatography variants and advanced tangential flow filtration approaches are raising the bar for manufacturing consistency and impurity clearance, and providers that combine these capabilities with robust fill-finish options will command differentiated value.

Finally, buyer expectations are changing: sponsors expect modular service offerings that can be tailored across preclinical, clinical, and commercial stages, with transparent tech transfer pathways and clear regulatory support. These transformative shifts favor integrated CDMOs that can demonstrate end-to-end capability while remaining flexible enough to support diverse therapeutic applications and serotype requirements.

A detailed impact analysis of tariff-driven supply chain dynamics and sourcing strategies that alter cost structures, supplier relationships, and program resilience in advanced vector production

The imposition of cumulative tariffs by the United States in 2025 has introduced a material sourcing complication for advanced biologics and their supporting supply chains, and the adeno-associated virus production ecosystem is no exception. Tariff-driven input cost inflation has pressured raw material sourcing choices, incentivized vertical integration of critical reagents, and prompted suppliers to reassess global procurement strategies. These responses are observable across upstream inputs such as plasmids, transfection reagents, single-use components, and chromatography resins, where shifting cost dynamics alter the calculus of insourcing versus outsourcing.

In addition to direct cost effects, tariffs have heightened attention to supply chain latency and single-source dependencies. Sponsors are increasingly requesting end-to-end visibility and multi-origin contingencies to mitigate the risk of interruption. The combination of higher landed costs and longer lead times has accelerated regionalization strategies; both sponsors and CDMOs are evaluating the trade-offs between centralized, high-efficiency facilities and localized capacity that reduces exposure to trade friction. Consequently, contract terms and supplier relationships are evolving to include more explicit clauses on cost-sharing, force majeure, and material substitution pathways.

Regulatory timelines are indirectly affected as well: when suppliers adjust sourcing or manufacturing footprints in response to tariffs, comparability assessments and supplemental filings can become necessary, extending program timelines if not proactively managed. For programs sensitive to time-to-patient, the most effective mitigation strategies include diversified vendor engagement, early supplier qualification, and contractual commitments that explicitly address tariff-related cost pass-through and resilience planning.

Comprehensive segmentation intelligence that connects service capabilities, production platforms, therapeutic priorities, and serotype selection to vendor suitability and program outcomes

Understanding market opportunity and vendor fit requires a deep appreciation of how service lines, production scales, expression systems, platforms, therapeutic targets, end users, and serotypes intersect to shape technical needs and partnership expectations. Service type considerations span analytical services, where potency and purity assays form the backbone of comparability and release decisions, as well as upstream processing choices between stable expression and transient transfection that determine batch consistency and timeline flexibility. Downstream processing encompasses chromatography and ultrafiltration workflows, with chromatography further divided into affinity and ion exchange modalities, and ultrafiltration commonly implemented as tangential flow filtration. Fill-finish capabilities range from pre-filled syringes to vial filling and are critical for clinical and commercial packaging strategies.

Production scale is equally pivotal, with preclinical, clinical, and commercial operations imposing distinct demands on process robustness, documentation, and capacity planning; clinical activities themselves span phase one, phase two, and phase three studies that progressively require higher throughput and regulatory rigor. Expression system choice between HEK293 and Sf9 influences vector yield, glycosylation profiles, and downstream purification strategies, while production platform selection-whether stable producer cell line approaches such as GTx platforms or transient transfection routes via liposome or polyethylenimine transfection-affects supply chain, IP considerations, and tech transfer complexity.

Therapeutic application drives potency, biodistribution, and serotype priorities: genetic diseases like hemophilia and muscular dystrophy may prioritize systemic dosing and certain serotype behaviors, whereas neurological disorders such as Alzheimer's and Parkinson's disease often necessitate CNS targeting considerations and tailored serotype deployment. End users range from academic research institutes to biotechnology and pharmaceutical companies, each bringing different regulatory experience, budget constraints, and timelines. Serotype prevalence across AAV2, AAV8, and AAV9 continues to guide vector selection based on tropism and immunogenicity profiles. Integrating these segmentation dimensions is essential for aligning vendor capabilities with program objectives and minimizing development risk.

Regional strategic considerations that explain how regulatory landscapes, talent pools, and logistics shape manufacturing footprints and supplier selection across global markets

Regional dynamics materially influence how sponsors and service providers prioritize capacity, regulatory engagement, and logistical planning across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, a concentration of clinical development activity and advanced manufacturing expertise supports rapid scale-up and close regulatory interaction, which benefits sponsors seeking tight coordination between process development and clinical programs. This region's supplier ecosystem tends to emphasize integrated service offerings, proximity to major developers, and expedited procurement cycles, all of which favor programs with aggressive timelines.

Europe, the Middle East & Africa presents a heterogeneous landscape where regulatory harmonization across larger markets coexists with localized manufacturing hubs. Providers in this region often navigate complex cross-border logistics and varying national regulatory expectations, leading to differentiated value propositions that include specialized analytical services, contract flexibility, and collaborative technology transfer models. The region's emphasis on rigorous comparability and patient safety makes it attractive for programs that prioritize high-assurance manufacturing and established regulatory pathways.

Asia-Pacific has emerged as a strategic node for capacity expansion and cost-competitive manufacturing, with rapidly growing infrastructure, skilled technical workforces, and an increasing number of facilities that support both clinical and commercial production. Sponsors can leverage suppliers in this region to optimize cost structures, but must carefully manage quality oversight, regulatory alignment, and supply chain continuity. Across all regions, the interplay of regulatory expectations, local talent pools, and logistics will determine the optimal distribution of process development and manufacturing activities for program sponsors seeking resilient and scalable supply chains.

Corporate capability mapping that highlights why validated analytics, diversified operations, and partnership-driven service models determine supplier competitiveness in vector manufacturing

Company-level dynamics are defining competitive differentiation in advanced vector production, with leading service providers demonstrating a combination of technical depth, regulatory experience, and operational scalability. Top-tier organizations typically invest heavily in validated analytical platforms, harmonized potency and purity assays, and standardized purification trains that reduce variability and speed comparability. These investments enable seamless transitions from clinical to commercial stages and support more predictable regulatory interactions.

Operational resilience is another axis of differentiation. Providers that have diversified supply chains, multi-site manufacturing footprints, and strong quality systems mitigate the risk of single-point failures and can offer sponsors capacity guarantees and contingency arrangements. Strategic partnerships and technology collaborations are increasingly common; CDMOs that align with platform technology developers or that host GTx-style stable producer cell line know-how can offer faster pathway options for programs that prioritize long-term commercial viability.

Finally, customer servicing models matter. Leading companies offer tailored engagements that include feasibility studies, accelerated tech transfer packages, and regulatory support services to simplify sponsor decisions. For sponsors, the choice of partner hinges on demonstrated track record with similar serotypes and therapeutic modalities, transparent performance metrics, and a willingness to proactively share risk through milestone-based commercial terms. As the field matures, company-level capability maps will continue to guide sponsor selection criteria and partnership structures.

Practical and enforceable recommendations for program sponsors to secure analytical robustness, platform flexibility, and supply chain resilience in contract and procurement strategies

Industry leaders should adopt actionable steps that translate strategic insight into operational and contractual advantage. First, integrate rigorous analytical benchmarking into vendor selection criteria by insisting on validated potency and orthogonal purity assays, well-documented method transfer protocols, and reproducibility metrics that minimize comparability risk during scale-up. Aligning analytical expectations early reduces downstream delays and clarifies regulatory pathways.

Second, prioritize flexible platform strategies that balance short-term clinical speed with long-term commercial stability. This means assessing the relative trade-offs between transient transfection and stable producer cell lines in the context of program duration, expected dosing, and immunogenicity considerations. Where appropriate, structure vendor engagements to allow phased transitions between platforms with predefined comparability studies and tech transfer milestones.

Third, mitigate supply chain and tariff exposure by qualifying multiple suppliers for critical inputs, negotiating contractual cost pass-through clauses for trade-related shocks, and considering regional capacity as part of procurement decisions. A proactive quality oversight program, including periodic audits and joint risk registers, will strengthen supplier relationships and reduce unexpected interruptions. Finally, embed regulatory readiness into contracts by specifying documentation deliverables, change management processes, and responsibilities for supplemental filings to ensure that process adjustments do not translate into timeline slippage.

A transparent mixed-methods approach that combines expert elicitation, technical literature synthesis, and scenario analysis to derive actionable insights for manufacturing decision-makers

The research methodology underpinning this analysis combines multi-dimensional evidence streams and structured expert elicitation to ensure robust, actionable insights. Primary inputs included interviews and structured consultations with manufacturing experts, analytical scientists, regulatory advisors, and procurement leaders who collectively provided qualitative perspectives on process selection, tech transfer complexity, and vendor capability. These primary insights were triangulated with secondary technical literature on vector biology, peer-reviewed methodological advances in chromatography and filtration, and public regulatory guidance on comparability and quality expectations.

Analytic rigor was achieved through cross-mapping of service capabilities against program stage needs, with scenario analysis used to explore the implications of different platform choices and regional sourcing strategies. Sensitivity checks focused on operational levers such as lead times for critical consumables, analytic method transfer effort, and the complexity of fill-finish qualification across device formats. The methodology emphasized transparency: assumptions about technology readiness, regulatory burden, and supply chain dependencies were documented and stress-tested with domain experts.

While quantitative metrics were not the objective of this qualitative study, the research approach ensured that conclusions are grounded in reproducible methods, expert consensus, and documented technology characteristics. This mixed-methods approach supports practical recommendations that are traceable to observed industry practices and validated technical considerations.

A conclusive synthesis that underscores the primacy of technical execution, regulatory alignment, and resilient sourcing to secure reliable manufacturing outcomes for gene therapy programs

The adeno-associated virus vector production ecosystem is at an inflection point where executional excellence, regulatory preparedness, and supply chain resilience will distinguish successful programs from those that encounter costly disruptions. Technical choices-such as expression system selection, platform strategy, and downstream purification architecture-have outsized influence on process robustness, comparability requirements, and time-to-patient. Sponsors that prioritize validated analytics, flexible platform roadmaps, and multi-origin procurement strategies will reduce program risk and preserve strategic optionality.

Additionally, the industry's evolving commercial dynamics favor partners that can demonstrate end-to-end capability while offering modularity across preclinical, clinical, and commercial stages. Regional considerations and tariff-related headwinds further complicate sourcing decisions, making early supplier qualification and contractual clarity indispensable. Ultimately, the most impactful advantage will accrue to organizations that convert technical insight into disciplined procurement and operational execution, thereby ensuring that scientific advances translate into reliable manufacturing outcomes and sustainable patient access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Adeno-Associated Virus Vector Production CDMO Market, by Service Type

  • 8.1. Analytical Services
    • 8.1.1. Potency Assay
    • 8.1.2. Purity Assay
  • 8.2. Downstream Processing
    • 8.2.1. Chromatography
      • 8.2.1.1. Affinity Chromatography
      • 8.2.1.2. Ion Exchange Chromatography
    • 8.2.2. Ultrafiltration
  • 8.3. Fill Finish
    • 8.3.1. Pre Fill Syringe
    • 8.3.2. Vial Filling
  • 8.4. Upstream Processing
    • 8.4.1. Stable Expression
    • 8.4.2. Transient Transfection

9. Adeno-Associated Virus Vector Production CDMO Market, by Production Scale

  • 9.1. Clinical
    • 9.1.1. Phase One
    • 9.1.2. Phase Three
    • 9.1.3. Phase Two
  • 9.2. Commercial
  • 9.3. Preclinical

10. Adeno-Associated Virus Vector Production CDMO Market, by Production Platform

  • 10.1. Stable Producer Cell Line
  • 10.2. Transient Transfection
    • 10.2.1. Liposome Transfection
    • 10.2.2. Polyethylenimine Transfection

11. Adeno-Associated Virus Vector Production CDMO Market, by Serotype

  • 11.1. AAV2
  • 11.2. AAV8
  • 11.3. AAV9

12. Adeno-Associated Virus Vector Production CDMO Market, by Therapeutic Application

  • 12.1. Genetic Diseases
    • 12.1.1. Hemophilia
    • 12.1.2. Muscular Dystrophy
  • 12.2. Neurological Disorders
    • 12.2.1. Alzheimers Disease
    • 12.2.2. Parkinsons Disease
  • 12.3. Oncology

13. Adeno-Associated Virus Vector Production CDMO Market, by End User

  • 13.1. Academic Research Institutes
  • 13.2. Biotechnology Companies
  • 13.3. Pharmaceutical Companies

14. Adeno-Associated Virus Vector Production CDMO Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Adeno-Associated Virus Vector Production CDMO Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Adeno-Associated Virus Vector Production CDMO Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Adeno-Associated Virus Vector Production CDMO Market

18. China Adeno-Associated Virus Vector Production CDMO Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AGC Biologics Co., Ltd.
  • 19.6. Aldevron, LLC
  • 19.7. BioCentriq, Inc.
  • 19.8. Catalent, Inc.
  • 19.9. Charles River Laboratories International, Inc.
  • 19.10. Creative Biogene, Inc.
  • 19.11. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 19.12. Genezen Laboratories, Inc.
  • 19.13. GenScript Biotech Corporation
  • 19.14. Kaneka Eurogentec S.A.
  • 19.15. Lonza Group AG
  • 19.16. Merck KGaA
  • 19.17. Novasep S.A.
  • 19.18. Oxford Biomedica PLC
  • 19.19. ProBio, Inc.
  • 19.20. Resilience, Inc.
  • 19.21. Samsung Biologics Co., Ltd.
  • 19.22. Thermo Fisher Scientific Inc.
  • 19.23. VGXI LLC
  • 19.24. Wuxi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY POTENCY ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY POTENCY ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY POTENCY ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PURITY ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PURITY ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PURITY ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ULTRAFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ULTRAFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRE FILL SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRE FILL SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRE FILL SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY VIAL FILLING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY VIAL FILLING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY VIAL FILLING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE EXPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE EXPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE EXPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHASE ONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHASE ONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHASE ONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHASE THREE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHASE THREE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHASE THREE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHASE TWO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHASE TWO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHASE TWO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE PRODUCER CELL LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE PRODUCER CELL LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY STABLE PRODUCER CELL LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY LIPOSOME TRANSFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY LIPOSOME TRANSFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY LIPOSOME TRANSFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY POLYETHYLENIMINE TRANSFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY POLYETHYLENIMINE TRANSFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY POLYETHYLENIMINE TRANSFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AAV2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AAV2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AAV2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AAV8, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AAV8, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AAV8, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AAV9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AAV9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY AAV9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY HEMOPHILIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY HEMOPHILIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY MUSCULAR DYSTROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY MUSCULAR DYSTROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY MUSCULAR DYSTROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ALZHEIMERS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ALZHEIMERS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ALZHEIMERS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PARKINSONS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PARKINSONS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PARKINSONS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY FILL FINISH, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY TRANSIENT TRANSFECTION, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY SEROTYPE, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC ADENO-ASSOCIATED VIRUS VECTOR PRODUCTION CDMO MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)

TABL